Enzo Biochem

$1.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.51%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell Enzo Biochem and other stocks, options, and ETFs commission-free!

About ENZ

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY. The listed name for ENZ is Enzo Biochem, Inc.

CEO
Elazar Rabbani
Employees
448
Headquarters
New York, New York
Founded
1976
Market Cap
94.35M
Price-Earnings Ratio
Dividend Yield
Average Volume
216.24K
High Today
$1.97
Low Today
$1.94
Open Price
$1.97
Volume
134.45K
52 Week High
$4.85
52 Week Low
$1.56

Collections

ENZ Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
per share
Actual
Expected Dec 8, After Hours

You May Also Like